Heather A. Shahzade

TL;DR: Direct prospective comparison of circulating tumor DNA and tissue biopsy sequencing shows the superiority of liquid biopsies for capturing clinically relevant alterations mediating resistance to targeted therapies in cancer patients.

TL;DR: Using an integrated multidisciplinary biopsy program, it is demonstrated that real-time genomic characterization of advanced PDAC can identify clinically relevant alterations that inform management of this difficult disease.

TL;DR: It is reported that the irreversible pan-FGFR inhibitor, TAS-120, demonstrated efficacy in four patients with FGFR2-fusion-positive ICC who developed resistance to BGJ398 or Debio1347 and suggests that strategic sequencing of FGFR inhibitors, guided by serial biopsies and ctDNA, may prolong the duration of benefit from FGFR inhibition in patients withFGFR2 fusion- positive ICC.

TL;DR: Feedback reactivation of wild-type RAS is identified as a key mechanism of adaptive resistance to KRASG12C inhibitors and the potential importance of vertical inhibition strategies to enhance the clinical efficacy of KRasG 12C inhibitors is highlighted.

TL;DR: Benton et al. as mentioned in this paper evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection, which demonstrated favorable sensitivity and specificity for recurrence.